University College London Hospitals Collaborate with AstraZeneca and IgniteData to Test SMART ON FHIR Based Tech
University College London Hospitals NHS Foundation Trust, IgniteData and AstraZeneca have successfully gone live in non-production (a mirror image of the live health record with synthetic non-sensitive patient data) testing with IgniteData’s HL7 FHIR enabled clinical trial data transfer platform, Archer. Testing will be conducted on UCLH’s Epic non-production EHR, before going live during Q4 2021 to automate the transfer of data into AstraZeneca’s Medidata Rave for an oncology study.
During 2022, IgniteData will collaborate with AstraZeneca to scale the standardized technology to other NHS and European hospitals. Archer is supervised by the investigator, meaning they maintain full control of which data leaves the hospital and no sensitive data is retained by Archer.
The project does not involve any new sharing of data, beyond the planned data sharing that will occur in the oncology research study. The work with Archer aims to improve the way in which data is transferred between systems.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
FOCUS Trial Results Show Solriamfetol Significantly Reduces ADHD Symptoms, Severity in Adults
March 27th 2025Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention-deficit hyperactivity disorder symptoms and disease severity in adults compared to placebo, with a favorable safety and tolerability profile.
